Abstract
Lung cancer is the leading cause of cancer death worldwide; its 5-year survival rate is only 15%. The therapy for this disease is improving with the advent of new targeted therapies, agents that are potentially more effective and less toxic. This has resulted from a better understanding of the molecular pathogenesis of this disease with the advent of new drugs or combinations for this disease. In February 2007, a 3-day conference in Santa Monica was sponsored by the International Association for the Study of Lung Cancer, which brought together 50 world experts in the treatment of this disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.